<DOC>
	<DOCNO>NCT00924898</DOCNO>
	<brief_summary>This pilot study treatment acute HIV infection daily regimen Emtricitabine , Tenofovir Efavirenz . The primary objective study : 1 . To determine safety tolerability , virologic immunologic efficacy FTC , TDF , efavirenz give daily patient acute HIV infection . 2 . To assess impact daily therapy combine standardized adherence program treatment adherence , virologic suppression , rate viral load decline blood infectious fluid ( semen , cervico-vaginal secretion ) . 3 . To define prevalence genotypic phenotypic resistance antiretroviral agent among person diagnose acute HIV infection Southeastern United States .</brief_summary>
	<brief_title>Treatment Acute HIV With Emtricitabine , Tenofovir Efavirenz ( CID 0805 )</brief_title>
	<detailed_description>Hypothesis : Once daily HAART FTC/TDF ( FDC , Truvada ) + EFV administer single dose pill call Atripla reduce viral replication &lt; 400 copy RNA/ml plasma blood body compartment patient acute HIV infection , reduce infectivity , permit generation HIV-specific immune response . The treatment regimen well tolerate lipid profile change modest treatment follow-up . A coordinated program counsel support facilitate adherence promote successful therapy . Prevalence transmit drug resistant HIV-1 assess . Study Design : Multi-center , prospective , single-arm pilot study FTC/TDF/EFV patient acute HIV infection . Study sit member Duke-UNC Acute HIV Infection Study Consortium . Patients follow intensively first year continue follow-up additional year pending development treatment cessation approach patient suppress virus effective immune response .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>1 . Diagnosis acute HIV infection define protocol . 2 . The following laboratory parameter verify within 30 day study entry : Bilirubin &lt; /= 3.0mg/dL ALT/AST &lt; /= 10 X upper limit normal Absolute neutrophil count ( ANC ) &gt; /= 500cells/mm3 Platelet count &gt; /= 25,000 cells/mm3 Hemoglobin &gt; /= 8.5g/dL men &gt; /= 8.0 g/dL woman Calculated creatinine clearance ( CockcroftGault formula ) &gt; /= 50mL/min : CrCl = ( 140age ) x body weight ( kg ) ( x 0.85 female ) / Serum creatinine [ mg/dL ] x ( 72 ) 3 . All woman childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit bHCG ) within 72 hour prior start study medication . WOCBP define female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) , postmenopausal ( define amenorrhea &gt; /=12 consecutive month ) , hormone replacement therapy ( HRT ) document plasma folliclestimulating hormone level &gt; /=35mLU/mL . Women use oral , implanted , injectable contraceptive hormone mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential ; 4 . Be willing use two effective form contraception throughout study . Barrier contraception always use combination method contraception ( oral hormonal contraceptive ) ; 5 . Weigh &gt; /= 40 kg ; 1 . A life expectancy less twelve month . 2 . Women pregnant breastfeeding . 3 . Women positive pregnancy test enrollment prior study drug administration . 4 . WOCBP unwilling unable use two acceptable method avoid pregnancy entire study period 5 . WOCBP use prohibit contraceptive method 6 . Hypersensitivity component formulation study drug . 7 . A clinically important illness explicitly exclude protocol , physical psychiatric disability , laboratory abnormality might place patient increase risk expose medication study might confound interpretation investigation . 8 . Proven suspect acute hepatitis within 30 day prior study entry ( exclude liver inflammation relate acute HIV infection ) . 9 . Intractable diarrhea ( &gt; /=6 loose stools/day least 7 consecutive day ) within 30 day prior study entry vomit last 4 day within one month prior dose ( excludes symptoms attribute acute HIV infection ) . 10 . An active AIDSdefining opportunistic infection disease ( purpose study , CD4 count &lt; /=200 cells/mm3 absence AIDSdefining indicator condition consider AIDSdefining event . AIDSdefining event occur acute HIV infection syndrome period Candida esophagitis consider casebycase basis automatically consider exclusionary ) . 11 . Inability communicate effectively study personnel . 12 . Current alcohol recreational drug use investigator 's opinion interfere subject 's ability comply dose schedule protocol evaluation increase risk develop pancreatitis . 13 . Incarceration ; prisoner recruitment participation permit . 14 . Difficulty swallow capsules/tablets . 15 . Prior treatment experimental drug indication ( within 30 day initiate study treatment ) . 16 . Treatment immunemodulating agent ( within 30 day initiate study treatment ) cyclosporine systemic corticosteroid . Routine vaccination allow . 17 . Therapy agent significant systemic neurotoxic , pancreatotoxic , cytotoxic potential within 3 month study start , need therapy expect time enrollment . 18 . Therapy nephrotoxic agent ( aminoglycosides , IV amphotericin , cidofovir , IV pentamidine , cisplatin agent nephrotoxic potential ) , adefovir probenecid . These agent must discontinue least 30 day prior start study medication . Brief course aminoglycosides within 30 day enrollment may allow discussion Study Chairs . 19 . Concomitant Medications : The following medication expressly prohibit course trial : Astemizole , cisapride , ergot derivative , hydroxyurea , midazolam , thalidomide , triazolam , vincristine , zalcitabine , ribavirin , doxorubicin , Voriconazole , St. John 's wort medication contraindicate concomitant use describe current product information packet insert ARV therapy use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Acute HIV</keyword>
	<keyword>HIV</keyword>
	<keyword>Acute Infections</keyword>
	<keyword>Acute Infection</keyword>
</DOC>